Refine
Has Fulltext
- yes (109)
Is part of the Bibliography
- yes (109)
Year of publication
Document Type
- Journal article (109) (remove)
Language
- English (109) (remove)
Keywords
- glycine receptor (8)
- neurons (5)
- spinal muscular atrophy (5)
- BDNF (4)
- hyperekplexia (4)
- amyotrophic lateral sclerosis (3)
- motoneurons (3)
- neurology (3)
- neuromuscular junction (3)
- startle disease (3)
- synaptic vesicles (3)
- Cys-loop receptor (2)
- Neurotrophic factors (2)
- RNA (2)
- TrkB (2)
- autoantibodies (2)
- autophagy (2)
- axons (2)
- binding (2)
- cerebellum (2)
- ciliary neurotrophic factor (2)
- cortical neurons (2)
- drosophila melanogaster (2)
- fear (2)
- growth cone (2)
- hippocampus (2)
- hybridomas (2)
- immunoprecipitation (2)
- melt electrowriting (2)
- neurofascin (2)
- neuropathic pain (2)
- pain (2)
- prefrontal cortex (2)
- receptor (2)
- spinal cord (2)
- synaptic inhibition (2)
- synaptic plasticity (2)
- 2-pore potassium channel (1)
- 3D cell culture (1)
- 3D cell cultures (1)
- 3D electrophysiology (1)
- 3D microfiber (1)
- 3D model systems (1)
- 3D neuronal networks (1)
- 3D tumor model (1)
- Aging (1)
- Alpha-synuclein oligomers (1)
- Alzheimer disease (1)
- Alzheimer's disease (1)
- Alzheimers disease (1)
- Alzheimer’s disease (1)
- Amyloid-beta oligomers; (1)
- Amyotrophic-lateral-sclerosis (1)
- Asc-1 transporter (1)
- Associative learning (1)
- Astrocytes ; Schwann cells ; Interferon-gamma ; Fibroblast growth factor ; Cyclic AMP (1)
- Autism spectrum disorders (1)
- Axon degeneration (1)
- Axon growth (1)
- Axonal transport (1)
- BDNF stimulation (1)
- BSTA (1)
- Brain (1)
- C. elegans (1)
- C9orf72 (1)
- COVID-19 (1)
- Ca\(^{2+}\)-Imaging (1)
- Ca\(_{v}\)2.2 (1)
- Cav2.2 (1)
- Cells (1)
- Cellular prion protein (1)
- Central nervous system (1)
- DAPI staining (1)
- DNA repeat expansion (1)
- DRD1 (1)
- Dentate granule cells (1)
- Down syndrome (1)
- Drosophilia (1)
- Exercise (1)
- F-actin (1)
- Facial Nerve Transection (1)
- Familial Alzheimers-disease (1)
- Fear conditioning (1)
- Fibroblast Growth Factor (1)
- GABA-A receptor (1)
- GABA\(_{A}\) (1)
- GABA\(_{A}\) receptor (1)
- GPCR (1)
- Glutamatergic synapses (1)
- GlyR receptors (1)
- GlyRs (1)
- Guillain-Barre-Syndrome (1)
- Hippocampus (1)
- IGF1 (1)
- IgG4 (1)
- Ighmbp2 (1)
- Immunopanning (1)
- Inhibitory glycine receptor (1)
- Insulinlike Growth Factor (1)
- Intermediate filaments (1)
- JNK (1)
- Kenyon cells (1)
- Lacking neurofilaments (1)
- Learning and memory (1)
- Lysosomal storage disease (1)
- MAP1B (1)
- MOC fibers (1)
- Microtubules (1)
- Missense mutation (1)
- Molecular neuroscience (1)
- Motoneuron disease (1)
- Motor behaviour (1)
- Motor neuron disease; Ciliary neurotrophic factor; Brain-derived neurotrophic factor; Animal models; Neurotrophic factors (1)
- Mouse model (1)
- Mus spretus (1)
- NMDAR (1)
- NMJ–neuromuscular junction (1)
- NaV1.9 (1)
- Nervenzelle (1)
- Neural circuits (1)
- Neurobiologie (1)
- Neurodegeneration (1)
- Neurofilament (1)
- Neuronal ceroid lipofuscinosis (1)
- Neurotrophin (1)
- Object recognition (1)
- Optical coherence tomography (1)
- P75 Neurotrophin receptor (1)
- PAG (1)
- PKA (1)
- PKB/Akt phosphorylation (1)
- PKC (1)
- PLEKHG5 (1)
- PTEN (1)
- Parkinson’s disease (1)
- Phosphorylation (1)
- Plasma-membrane (1)
- Pleckstrin homology containing family member 5 (Plekhg5) (1)
- Progressive motor neuronopathy (1)
- Protein kinase B (1)
- RHO (1)
- RNA splicing (1)
- RNA transport (1)
- RNA-binding proteins (1)
- ROCK (1)
- Retinal degeneration (1)
- Rictor-mTOR complex (1)
- SAP47 gene (1)
- SARS-CoV- 2 (1)
- SMARD1 (1)
- SMN (1)
- SMN granules (1)
- Sap47 (1)
- Schwann cells (1)
- Spinal Muscular-arthropy (1)
- Stat3 (1)
- Stathmin (1)
- Syap1 knockout (1)
- Syap1 localization (1)
- T-cadherin (1)
- TRP channel (1)
- Temporal-lobe epilepsy (1)
- Transcription (1)
- Transgenic mice (1)
- Vascular plasticity (1)
- Viability (1)
- YB-1 (1)
- actin messenger RNA (1)
- activation (1)
- activators/inhibitors of phosphorylation (1)
- adenocarcinoma of the lung (1)
- adsorption (1)
- allosteric modulation (1)
- alpha-7 nicotinic acetylcholine receptor (1)
- amoeboid cell migration (1)
- amygdala (1)
- analgesia (1)
- antibodies (1)
- antigen processing and recognition (1)
- anxiety (1)
- apoptosis (1)
- astrocytes (1)
- autism (1)
- autoantibody (aAb) (1)
- autoimmune antibodies (1)
- autoimmune nodopathy (1)
- axon growth (1)
- barrier (1)
- basal ganglia (1)
- behavioral disorders (1)
- biopsies (1)
- brain (1)
- brain cancer (1)
- breast cancer (1)
- c-Jun (1)
- cadherin-13 (CDH13) (1)
- calcium channels (1)
- candidate gene (1)
- cardiology (1)
- cell death (1)
- cell staining (1)
- cells (1)
- cerebral amyloid angiopathy (1)
- cerebral blood flow (1)
- cerebral small vessel disease (1)
- channel (1)
- choline acetyltransferase (1)
- chronic pain (1)
- ciliary neuron (1)
- ciliary-neurotrophic factor (1)
- circuits and circuit components (1)
- claudin-5 (1)
- click-chemistry (1)
- clinical neurology (1)
- cochlea (1)
- comet assay (1)
- contactin (1)
- cortico-striatal synapse (1)
- cross-sectional studies (1)
- cytosol (1)
- dSPN (1)
- dSTORM (1)
- deep brain stimulation (1)
- defensive states (1)
- degeneration (1)
- demyelination (1)
- dentate gyrus (1)
- determining gene-product (1)
- direct pathway (1)
- domain (1)
- domain K\(^{+}\) channels (1)
- dominant (1)
- dorsal raphe (1)
- dorsal root ganglion (1)
- durotaxis (1)
- dynamics of ribosomal assembly (1)
- early-onset predictors (1)
- electron tomography (1)
- embryos (1)
- emotional states (1)
- energy metabolism (1)
- enrichment (1)
- epilepsy (1)
- exercise (1)
- extracellular domain (1)
- factor prevents (1)
- fast decay (1)
- fluorescence in-situ hybridization (1)
- frontotemporal dementia (1)
- fused in sarcoma (1)
- gait (1)
- gel electrophoresis (1)
- gene expression (1)
- genetic code expansion (1)
- genome wide (1)
- genome-wide association studies (1)
- gephyrin (1)
- glycine receptor (GlyR) (1)
- glycine receptor autoantibodies (1)
- glycine transporter 2 (1)
- glycine uptake (1)
- glycogen phosphorylase (1)
- glycogen synthase (1)
- glycolysis (1)
- glycosylation (1)
- glyvine uptake (1)
- granule cells (1)
- hearing loss (1)
- heart rate (1)
- hippocampal neurons (1)
- homologous recombination (1)
- human startle disease (1)
- hyaluronic acid (1)
- hypertensive arteriopathy (1)
- iPSC (induced pluripotent stem cells) (1)
- immune response (1)
- immune serum (1)
- immunocytochemical analysis (1)
- immunohistochemistry techniques (1)
- inflammatory demyelinating polyradiculoneuropathy (1)
- inflammatory neuropathy (1)
- initiation (1)
- injury (1)
- insulin (1)
- insulin-likegrowth factor I (1)
- interaction partners (1)
- interacts (1)
- interleukin 6 (1)
- interspeific backcross (1)
- intracellular domain (1)
- intravital imaging (1)
- ion channel (1)
- ion channels in the nervous system (1)
- knockout mice (1)
- larval drosophila (1)
- library screening (1)
- ligand potencies (1)
- linalool (1)
- linalyl acetate (1)
- linkage (1)
- lithium (1)
- local protein synthesis (1)
- locomotion (1)
- loop B (1)
- loss of function (1)
- lung and intrathoracic tumors (1)
- mRNA localization (1)
- machine learning (1)
- macrophages (1)
- mechanisms (1)
- medicine (1)
- memory (1)
- mesencephalic locomotor region (1)
- metastasis (1)
- microscopy (1)
- microtubules (1)
- migraine (1)
- mild cognitive impairment (1)
- mimetic peptide (1)
- modulation (1)
- modulation kinetics (1)
- molecular mechanisms (1)
- molecular medicine (1)
- molecular neuroscience (1)
- monoclonal antibodies (1)
- motoneuron (1)
- motoneuron (MN) (1)
- motoneuron disease (1)
- motor axon (1)
- motor axons (1)
- motor control (1)
- motor learning (1)
- motor neuron degeneration (1)
- motor neurons (1)
- motor neuropathy (1)
- mouse (1)
- mouse model (1)
- movement disorders (1)
- mulitple-sclerosis patients (1)
- mushroom body (1)
- musk myasthenia gravis (1)
- mutations (1)
- myelin (1)
- nerve injury (1)
- nerve ultrasonography (1)
- nervous system (1)
- neural networks (1)
- neurodegeneration (1)
- neurodevelopment (1)
- neurofilaments (1)
- neuroinflammation (1)
- neuron migration (1)
- neuronal dendrites (1)
- neuronal differentiation (1)
- neuronal networks (1)
- neuronal primary culture (1)
- neuropathy (1)
- neuropil (1)
- neuroscience (1)
- neurotrophins (1)
- nifedipine (1)
- nociception (1)
- node of ranvier (1)
- non-small cell lung cancer (1)
- nonneuronaI cells (1)
- nuclear ribonucleoprotein-R (1)
- ontactin 1 (1)
- outer hair cell (OHC) (1)
- oxidized phospholipids (1)
- oxygenation (1)
- pain therapy (1)
- passive transfer (1)
- patch clamp recording (1)
- patch-clamp (1)
- pegylated insulin-like growth factor 1 (1)
- periperal nerve (1)
- peripheral neuropathy (1)
- phosphorylase isozymes (1)
- phosphorylation (1)
- photothrombotic stroke (1)
- postsynaptic potentials (1)
- posttranslational modifications (1)
- prediction error (1)
- presynapse (1)
- presynaptic ER dynamics (1)
- presynaptic hyperekplexia (1)
- programmed cell death (1)
- progressive encephalitis with rigidity and myoclonus (PERM) (1)
- protein coupled receptors (1)
- protein interactions (1)
- protein maturation (1)
- protein synthesis (1)
- protein transport (1)
- psychiatric disorders (1)
- quality control (1)
- radial glia (1)
- receptor internalization (1)
- recombinant proteins (1)
- regulation (1)
- rescue (1)
- restriction fragment length polymorphism (1)
- roles (1)
- secondary lung tumors (1)
- sensory neurons (1)
- serotonin (1)
- short-term memory (1)
- side chain properties (1)
- silver staining (1)
- site (1)
- skeletal muscle (1)
- sodium channel (1)
- software (1)
- spastic (1)
- spinal cord neurons (1)
- spontaneous excitation (1)
- spontaneous mouse mutants (1)
- spontaneously hypertensive stroke-prone rat (1)
- startle (1)
- startle reaction (1)
- stiff-person syndrome (SPS) (1)
- stroke (1)
- structural disruption (1)
- subcellular trafficking (1)
- super-resolution microscopy (SRM) (1)
- superficial peroneal nerve (1)
- sural nerve (1)
- survey (1)
- survival (1)
- switch (1)
- synapse structure (1)
- synapses (1)
- synaptic localization (1)
- synaptic transmission (1)
- synthase (1)
- systems biology (1)
- telemedicine (1)
- therapeutic antibody (1)
- thoracic diaphragm (1)
- tight junction (1)
- topotaxis (1)
- trafficking (1)
- trafficking pathways (1)
- transactivation (1)
- transport (1)
- trkB (1)
- trophic/potassium deprivation (1)
- uper-resolution array tomography (1)
- vasculitis (1)
- vector cloning (1)
- whole-cell currents (1)
- α-synuclein-specific T cells (1)
- β-actin mRNA (1)
- β8-β9 loop (1)
Institute
- Institut für Klinische Neurobiologie (109) (remove)
Background
While it is now apparent clinical sequelae (long COVID) may persist after acute COVID-19, their nature, frequency and aetiology are poorly characterised. This study aims to regularly synthesise evidence on long COVID characteristics, to help inform clinical management, rehabilitation strategies and interventional studies to improve long-term outcomes.
Methods
A living systematic review. Medline, CINAHL (EBSCO), Global Health (Ovid), WHO Global Research on COVID-19 database, LitCovid and Google Scholar were searched till 17 March 2021. Studies including at least 100 people with confirmed or clinically suspected COVID-19 at 12 weeks or more post onset were included. Risk of bias was assessed using the tool produced by Hoy et al. Results were analysed using descriptive statistics and meta-analyses to estimate prevalence.
Results
A total of 39 studies were included: 32 cohort, 6 cross-sectional and 1 case–control. Most showed high or moderate risk of bias. None were set in low-income countries and few included children. Studies reported on 10 951 people (48% female) in 12 countries. Most included previously hospitalised people (78%, 8520/10 951). The longest mean follow-up time was 221.7 (SD: 10.9) days post COVID-19 onset. Over 60 physical and psychological signs and symptoms with wide prevalence were reported, most commonly weakness (41%; 95% CI 25% to 59%), general malaise (33%; 95% CI 15% to 57%), fatigue (31%; 95% CI 24% to 39%), concentration impairment (26%; 95% CI 21% to 32%) and breathlessness (25%; 95% CI 18% to 34%). 37% (95% CI 18% to 60%) of patients reported reduced quality of life; 26% (10/39) of studies presented evidence of reduced pulmonary function.
Conclusion
Long COVID is a complex condition with prolonged heterogeneous symptoms. The nature of studies precludes a precise case definition or risk evaluation. There is an urgent need for prospective, robust, standardised, controlled studies into aetiology, risk factors and biomarkers to characterise long COVID in different at-risk populations and settings.
PROSPERO registration number CRD42020211131.
Precise quantitative information about the molecular architecture of synapses is essential to understanding the functional specificity and downstream signaling processes at specific populations of synapses. Glycine receptors (GlyRs) are the primary fast inhibitory neurotransmitter receptors in the spinal cord and brainstem. These inhibitory glycinergic networks crucially regulate motor and sensory processes. Thus far, the nanoscale organization of GlyRs underlying the different network specificities has not been defined. Here, we have quantitatively characterized the molecular arrangement and ultra-structure of glycinergic synapses in spinal cord tissue using quantitative super-resolution correlative light and electron microscopy. We show that endogenous GlyRs exhibit equal receptor-scaffold occupancy and constant packing densities of about 2000 GlyRs µm-2 at synapses across the spinal cord and throughout adulthood, even though ventral horn synapses have twice the total copy numbers, larger postsynaptic domains, and more convoluted morphologies than dorsal horn synapses. We demonstrate that this stereotypic molecular arrangement is maintained at glycinergic synapses in the oscillator mouse model of the neuromotor disease hyperekplexia despite a decrease in synapse size, indicating that the molecular organization of GlyRs is preserved in this hypomorph. We thus conclude that the morphology and size of inhibitory postsynaptic specializations rather than differences in GlyR packing determine the postsynaptic strength of glycinergic neurotransmission in motor and sensory spinal cord networks.
Chemicals reactivating epigenetically silenced genes target diverse classes of enzymes, including DNMTs, HDACs, HMTs and BET protein family members. They can strongly influence the expression of genes and endogenous retroviral elements with concomitant dsRNA synthesis and massive transcription of LTRs. Chemicals reactivating gene expression may cause both beneficial effects in cancer cells and may be hazardous by promoting carcinogenesis. Among chemicals used in medicine and commerce, only a small fraction has been studied with respect to their influence on epigenetic silencing. Screening of chemicals reactivating silent genes requires adequate systems mimicking whole-genome processes. We used a HeLa TSA-inducible cell population (HeLa TI cells) obtained by retroviral infection of a GFP-containing vector followed by several rounds of cell sorting for screening purposes. Previously, the details of GFP epigenetic silencing in HeLa TI cells were thoroughly described. Herein, we show that the epigenetically repressed gene GFP is reactivated by 15 agents, including HDAC inhibitors–vorinostat, sodium butyrate, valproic acid, depsipeptide, pomiferin, and entinostat; DNMT inhibitors–decitabine, 5-azacytidine, RG108; HMT inhibitors–UNC0638, BIX01294, DZNep; a chromatin remodeler–curaxin CBL0137; and BET inhibitors–JQ-1 and JQ-35. We demonstrate that combinations of epigenetic modulators caused a significant increase in cell number with reactivated GFP compared to the individual effects of each agent. HeLa TI cells are competent to metabolize xenobiotics and possess constitutively expressed and inducible cytochrome P450 mono-oxygenases involved in xenobiotic biotransformation. Thus, HeLa TI cells may be used as an adequate test system for the extensive screening of chemicals, including those that must be metabolically activated. Studying the additional metabolic activation of xenobiotics, we surprisingly found that the rat liver S9 fraction, which has been widely used for xenobiotic activation in genotoxicity tests, reactivated epigenetically silenced genes. Applying the HeLa TI system, we show that N-nitrosodiphenylamine and N-nitrosodimethylamine reactivate epigenetically silenced genes, probably by affecting DNA methylation.
We aimed to test the hypothesis that in spontaneously hypertensive stroke-prone rats (SHRSP), non-amyloid cerebral small vessel disease/hypertensive arteriopathy (HA) results in vessel wall injury that may promote cerebral amyloid angiopathy (CAA). Our study comprised 21 male SHRSP (age 17–44 weeks) and 10 age- and sex-matched Wistar control rats, that underwent two-photon (2PM) imaging of the arterioles in the parietal cortex using Methoxy-X04, Dextran and cerebral blood flow (CBF) measurements. Our data suggest that HA in SHRSP progresses in a temporal and age-dependent manner, starting from small vessel wall damage (stage 1A), proceeding to CBF reduction (stage 1B), non-occlusive (stage 2), and finally, occlusive thrombi (stage 3). Wistar animals also demonstrated small vessel wall damage, but were free of any of the later HA stages. Nearly half of all SHRSP additionally displayed vascular Methoxy-X04 positivity indicative of cortical CAA. Vascular β-amyloid deposits were found in small vessels characterized by thrombotic occlusions (stage 2 or 3). Post-mortem analysis of the rat brains confirmed the findings derived from intravital 2PM microscopy. Our data thus overall suggest that advanced HA may play a role in CAA development with the two small vessel disease entities might be related to the same pathological spectrum of the aging brain.
Glycine receptors (GlyRs) are important mediators of fast inhibitory neurotransmission in the mammalian central nervous system. Their function is controlled by multiple cellular mechanisms, including intracellular regulatory processes. Modulation of GlyR function by protein kinases has been reported for many cell types, involving different techniques, and often yielding contradictory results. Here, we studied the effects of protein kinase C (PKC) and cAMP-dependent protein kinase A (PKA) on glycine induced currents in HEK293 cells expressing human homomeric \(\alpha\)1 and heteromeric \(\alpha\)1-\(\beta\) GlyRs using whole-cell patch clamp techniques as well as internalization assays. In whole-cell patch-clamp measurements, modulators were applied in the intracellular buffer at concentrations between 0.1 \(\mu\)M and 0.5 \(\mu\)M. EC50 of glycine increased upon application of the protein kinase activators Forskolin and phorbol-12-myristate-13-acetate (PMA) but decreased in the presence of the PKC inhibitor Staurosporine aglycon and the PKA inhibitor H-89. Desensitization of recombinant \(\alpha\)1 receptors was significantly increased in the presence of Forskolin. Staurosporine aglycon, on the other hand decreased desensitization of heteromeric \(\alpha\)1-\(\beta\) GlyRs. The time course of receptor activation was determined for homomeric \(\alpha\)1 receptors and revealed two simultaneous effects: cells showed a decrease of EC50 after 3-6 min of establishing whole-cell configuration. This effect was independent of protein kinase modulators. All modulators of PKA and PKC, however, produced an additional shift of EC50, which overlay and eventually exceeded the cells intrinsic variation of EC50. The effect of kinase activators was abolished if the corresponding inhibitors were co-applied, consistent with PKA and PKC directly mediating the modulation of GlyR function. Direct effects of PKA-and PKC-modulators on receptor expression on transfected HEK cells were monitored within 15 min of drug application, showing a significant increase of receptor internalization with PKA and PKC activators, while the corresponding inhibitors had no significant effect on receptor surface expression or internalization. Our results confirm the observation that phosphorylation via PKA and PKC has a direct effect on the GlyR ion channel complex and plays an important role in the fine-tuning of glycinergic signaling.
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease that affects 1 in ~350 individuals. Genetic association studies have established ALS as a multifactorial disease with heritability estimated at ~61%, and recent studies show a prominent role for rare variation in its genetic architecture. To identify rare variants associated with disease onset we performed exome array genotyping in 4,244 cases and 3,106 controls from European cohorts. In this largest exome-wide study of rare variants in ALS to date, we performed single-variant association testing, gene-based burden, and exome-wide individual set-unique burden (ISUB) testing to identify single or aggregated rare variation that modifies disease risk. In single-variant testing no variants reached exome-wide significance, likely due to limited statistical power. Gene-based burden testing of rare non-synonymous and loss-of-function variants showed NEK1 as the top associated gene. ISUB analysis did not show an increased exome-wide burden of deleterious variants in patients, possibly suggesting a more region-specific role for rare variation. Complete summary statistics are released publicly. This study did not implicate new risk loci, emphasizing the immediate need for future large-scale collaborations in ALS that will expand available sample sizes, increase genome coverage, and improve our ability to detect rare variants associated to ALS.
Despite fine tuning voluntary movement as the most prominently studied function of the cerebellum, early human studies suggested cerebellar involvement emotion regulation. Since, the cerebellum has been associated with various mood and anxiety-related conditions. Research in animals provided evidence for cerebellar contributions to fear memory formation and extinction. Fear and anxiety can broadly be referred to as defensive states triggered by threat and characterized by multimodal adaptations such as behavioral and cardiac responses integrated into an intricately orchestrated defense reaction. This is mediated by an evolutionary conserved, highly interconnected network of defense-related structures with functional connections to the cerebellum. Projections from the deep cerebellar nucleus interpositus to the central amygdala interfere with retention of fear memory. Several studies uncovered tight functional connections between cerebellar deep nuclei and pyramis and the midbrain periaqueductal grey. Specifically, the fastigial nucleus sends direct projections to the ventrolateral PAG to mediate fear-evoked innate and learned freezing behavior. The cerebellum also regulates cardiovascular responses such as blood pressure and heart rate-effects dependent on connections with medullary cardiac regulatory structures. Because of the integrated, multimodal nature of defensive states, their adaptive regulation has to be highly dynamic to enable responding to a moving threatening stimulus. In this, predicting threat occurrence are crucial functions of calculating adequate responses. Based on its role in prediction error generation, its connectivity to limbic regions, and previous results on a role in fear learning, this review presents the cerebellum as a regulator of integrated cardio-behavioral defensive states.
Glycine receptor (GlyR) autoantibodies are associated with stiff-person syndrome and the life-threatening progressive encephalomyelitis with rigidity and myoclonus in children and adults. Patient histories show variability in symptoms and responses to therapeutic treatments. A better understanding of the autoantibody pathology is required to develop improved therapeutic strategies. So far, the underlying molecular pathomechanisms include enhanced receptor internalization and direct receptor blocking altering GlyR function. A common epitope of autoantibodies against the GlyRα1 has been previously defined to residues 1A-33G at the N-terminus of the mature GlyR extracellular domain. However, if other autoantibody binding sites exist or additional GlyR residues are involved in autoantibody binding is yet unknown. The present study investigates the importance of receptor glycosylation for binding of anti-GlyR autoantibodies. The glycine receptor α1 harbors only one glycosylation site at the amino acid residue asparagine 38 localized in close vicinity to the identified common autoantibody epitope. First, non-glycosylated GlyRs were characterized using protein biochemical approaches as well as electrophysiological recordings and molecular modeling. Molecular modeling of non-glycosylated GlyRα1 did not show major structural alterations. Moreover, non-glycosylation of the GlyRα1N38Q did not prevent the receptor from surface expression. At the functional level, the non-glycosylated GlyR demonstrated reduced glycine potency, but patient GlyR autoantibodies still bound to the surface-expressed non-glycosylated receptor protein in living cells. Efficient adsorption of GlyR autoantibodies from patient samples was possible by binding to native glycosylated and non-glycosylated GlyRα1 expressed in living not fixed transfected HEK293 cells. Binding of patient-derived GlyR autoantibodies to the non-glycosylated GlyRα1 offered the possibility to use purified non-glycosylated GlyR extracellular domain constructs coated on ELISA plates and use them as a fast screening readout for the presence of GlyR autoantibodies in patient serum samples. Following successful adsorption of patient autoantibodies by GlyR ECDs, binding to primary motoneurons and transfected cells was absent. Our results indicate that the glycine receptor autoantibody binding is independent of the receptor’s glycosylation state. Purified non-glycosylated receptor domains harbouring the autoantibody epitope thus provide, an additional reliable experimental tool besides binding to native receptors in cell-based assays for detection of autoantibody presence in patient sera.
Introduction
IgG4 autoantibodies against paranodal proteins are known to induce acute-onset and often severe sensorimotor autoimmune neuropathies. How autoantibodies reach their antigens at the paranode in spite of the myelin barrier is still unclear.
Methods
We performed in vitro incubation experiments with patient sera on unfixed and unpermeabilized nerve fibers and in vivo intraneural and intrathecal passive transfer of patient IgG to rats, to explore the access of IgG autoantibodies directed against neurofascin-155 and contactin-1 to the paranodes and their pathogenic effect.
Results
We found that in vitro incubation resulted in weak paranodal binding of anti-contactin-1 autoantibodies whereas anti-neurofascin-155 autoantibodies bound to the nodes more than to the paranodes. After short-term intraneural injection, no nodal or paranodal binding was detectable when using anti-neurofascin-155 antibodies. After repeated intrathecal injections, nodal more than paranodal binding could be detected in animals treated with anti-neurofascin-155, accompanied by sensorimotor neuropathy. In contrast, no paranodal binding was visible in rats intrathecally injected with anti-contactin-1 antibodies, and animals remained unaffected.
Conclusion
These data support the notion of different pathogenic mechanisms of anti-neurofascin-155 and anti-contactin-1 autoantibodies and different accessibility of paranodal and nodal structures.
Highlights
• Dopamine receptor-1 activation induces TrkB cell-surface expression in striatal neurons
• Dopaminergic deficits cause TrkB accumulation and clustering in the ER
• TrkB clusters colocalize with cargo receptor SORCS-2 in direct pathway striatal neurons
• Intracellular TrkB clusters fail to fuse with lysosomes after dopamine depletion
Summary
Disturbed motor control is a hallmark of Parkinson’s disease (PD). Cortico-striatal synapses play a central role in motor learning and adaption, and brain-derived neurotrophic factor (BDNF) from cortico-striatal afferents modulates their plasticity via TrkB in striatal medium spiny projection neurons (SPNs). We studied the role of dopamine in modulating the sensitivity of direct pathway SPNs (dSPNs) to BDNF in cultures of fluorescence-activated cell sorting (FACS)-enriched D1-expressing SPNs and 6-hydroxydopamine (6-OHDA)-treated rats. DRD1 activation causes enhanced TrkB translocation to the cell surface and increased sensitivity for BDNF. In contrast, dopamine depletion in cultured dSPN neurons, 6-OHDA-treated rats, and postmortem brain of patients with PD reduces BDNF responsiveness and causes formation of intracellular TrkB clusters. These clusters associate with sortilin related VPS10 domain containing receptor 2 (SORCS-2) in multivesicular-like structures, which apparently protects them from lysosomal degradation. Thus, impaired TrkB processing might contribute to disturbed motor function in PD.